This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

New Survey Shows Patients Oppose "Prescription-Only" Laws For Some Common Medications

Asthma and Allergy Foundation Poll Finds Patients Already Have Many Healthcare Challenges

WASHINGTON , Feb. 22, 2013 /PRNewswire-USNewswire/ -- The Asthma and Allergy Foundation of America (AAFA) is out with a new poll re-confirming what AAFA already learned from a previous study and from 60 years of continual nonprofit service to the asthma and allergy community: patients nationwide strongly oppose proposed laws to change popular over-the-counter (OTC) medications to prescription-only (Rx) status.

The new poll was conducted online by Harris Interactive in January 2013, among over 2,000 U.S. adults who personally suffered from asthma, allergies, cold, cough or flu in the preceding 12 months and who purchased non-prescription medications for at least one condition during that time.

More than 45 million Americans have nasal allergies, more than 22 million have asthma and over 10 million have both. Respiratory diseases take a devastating toll on public health, costing billions of dollars in direct medical expenses, reducing quality of life, lowering workplace and school performance, and can even be life-threatening to high-risk populations, such as asthma patients. 

That's why so many families rely on quick and affordable access to effective FDA-approved OTC and Rx medications for controlling symptoms of these diseases. "It's easy for AAFA to be on the patients' side of this issue," says Charlotte Collins, AAFA's Vice President of Policy & Programs. "The data shows us that patients already deal with the burdens of these chronic diseases, so adding restrictions on top of the burdens they already face would be a real problem. And they feel the best way to stop criminals involved in the illegal meth trade is through law enforcement and other proven methods, not by doctors' prescriptions." 

"This is just common sense," Collins continued. "Meth crimes are serious, with sometimes tragic outcomes, but doctors are not substitutes for police, and patients should not be penalized for crimes by meth makers."

Creating More Burdens for Patients Is the Wrong Approach

Over 18 million households in the U.S. depend on OTC medicines containing pseudoephedrine (PSE) to relieve their common symptoms, but direct and immediate access to these medications for patients continues to be threatened by some states looking at requiring prescriptions as a way to stop illegal meth makers. Now, patients are speaking up to let policy makers know that this is not the right solution. In recent years, policymakers in a number of states have proposed Rx-only laws that were eventually defeated in large part because patients and families are overwhelmingly opposed them.

Following AAFA's first poll in 2010 showing that the majority of asthma, allergy, cold and flu patients opposed changing popular OTC medications to Rx status, the nonprofit patient organization worked with Harris Interactive to conduct a 2013 follow-up study to look more into the burdens that patients face. The results show that a clear majority (62%) of patients are opposed to Rx-only restrictions. Additionally, AAFA's 2013 study looked beyond the original set of questions asked in 2010 to gain a better understanding of burdens patients currently face and how those burdens would be impacted by a PSE prescription requirement.  

Survey results show that patients already face costs and burdens associated with treating their common symptoms. 

  • Two-thirds of patients (64%) say they are managing medications for 2 or more people in their household
  • Patient households deal with allergy symptoms for more than 2 months per year (69.5 days on average)
  • Only 1-in-five patients can get in to see their doctor the same day, with nearly one quarter (22%) having to wait more than a week  to get an appointment
  • Patients say that two in five (42%) of their visits to the doctor require time off of work, with one-third (31%) saying that their doctor visits always take place during their work hours
  • When including drive time, waiting-room time and the visit itself, only 1-in-five patients surveyed spend less than an hour when visiting the doctor, with nearly one-third (30%) requiring 2 or more hours per visit; one-in-ten (9%) require 3 or more hours per visit
  • The majority of patients surveyed (59%) spend at least $20 per doctor visit, plus 4-out-of-5 of them (82%) are also paying to fill prescriptions frequently or occasionally for themselves or family members

AAFA has posted more information online for the public and policymakers at  www.aafa.org/pse so people can learn what to do in their own states to fight meth while also preserving access to OTC medications.

"Patients are really concerned about extreme local laws that limit their freedom to access meds," says Collins. "AAFA is working with patients nationwide to teach lawmakers about better solutions. We want to make sure that the patient voice is heard." 

About the Survey AAFA's National Pseudoephedrine (PSE) Awareness Study was conducted online between January 4 – 15, 2013 among 2,020 U.S. adults age 18+ who personally suffered from asthma, allergies, cold, cough or flu in the preceding 12 months and purchased non-prescription medications for at least one condition during that time. The poll was conducted for AAFA by Harris Interactive, supported by a grant from the Consumer Healthcare Products Association (CHPA). The study used Harris Interactive's proprietary propensity weighting to ensure the online sample reflects general population trends.

About AAFA The Asthma and Allergy Foundation of America (AAFA), a not-for-profit organization founded in 1953, is the leading patient organization for people with asthma, allergies and related conditions. AAFA is dedicated to improving the quality of life for patients through education, advocacy and research. AAFA provides practical information, community based services and support through a network of regional chapters, support groups and other local partners around the United States. For more information, visit www.aafa.org.

About Harris Interactive Harris Interactive is one of the world's leading custom market research firms, leveraging research, technology, and business acumen to transform relevant insight into actionable foresight. Known widely for the Harris Poll and for pioneering innovative research methodologies, Harris offers expertise in a wide range of industries including healthcare, technology, public affairs, energy, telecommunications, financial services, insurance, media, retail, restaurant, and consumer package goods. Serving clients in over 215 countries and territories through our North American, European, and Asian offices and a network of independent market research firms, Harris specializes in delivering research solutions that help us – and our clients – stay ahead of what's next. For more information, please visit www.harrisinteractive.com.

SOURCE The Asthma and Allergy Foundation of America

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,805.82 +27.67 0.16%
S&P 500 2,072.96 +11.73 0.57%
NASDAQ 4,773.0150 +24.6190 0.52%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs